Search - tctmd.com

Displaying 161 - 180 of 276

Sort: Relevancy | Date

News Daily News

Gasp! Cardiorespiratory Fitness Falling Over Time, Duke Study Suggests

Michael O'Riordan

January 23, 2019

News Features

Top News in Prevention: 2018

Michael O'Riordan

December 28, 2018

News Daily News

Now You See It: Imaging Helps Lower CVD Risk Burden in Primary Prevention

Michael O'Riordan

December 10, 2018

News Daily News

SYNTAX Score Should Not Guide Revascularization Strategy in FREEDOM-Like Patients

Michael O'Riordan

December 04, 2018

News Daily News

Higher Rates of Amputation and Ketoacidosis With SGLT2 Inhibitors: European Registry Data

Michael O'Riordan

November 26, 2018

News Daily News

PIONEER 6: Oral Semaglutide Passes Test in Cardiovascular Outcomes Study

Michael O'Riordan

November 23, 2018

News Conference News AHA 2018

EMPA-HEART Offers Mechanistic Clues for Empagliflozin’s Cardiac Benefits

Michael O'Riordan

November 16, 2018

News Conference News AHA 2018

Long-term FREEDOM: At Nearly 8 years, CABG Maintains Mortality Benefit Over PCI

Michael O'Riordan

November 14, 2018

News Conference News AHA 2018

Sit Less, Move More: New Physical Activity Guidelines Stress Movement at All Ages

Michael O'Riordan

November 12, 2018

News Conference News AHA 2018

New Cholesterol Guidelines Make Room for Non-Statin Therapy and CAC Screening

Michael O'Riordan

November 10, 2018

News Daily News

Big Fitness Equals Big Survival Benefit, New Study Shows

Michael O'Riordan

October 22, 2018

News Features

The Price of Knowledge: Industry-Sponsored Studies in the Era of Evidence-Based Medicine

Shelley Wood

October 22, 2018

News Daily News

Bariatric Surgery Reduces Hard CVD Events in Obese Patients With Type 2 Diabetes

Michael O'Riordan

October 18, 2018

News Daily News

Statin Benefits: Yes for CVD but No for Everything Else, Says New Review

Michael O'Riordan

October 08, 2018

News Conference News ESC 2018

Omega-3 Fatty Acids Fail to Reduce CVD Events in Diabetic Patients: ASCEND

Michael O'Riordan

August 26, 2018

News Conference News ESC 2018

Weight-Loss Drug Lorcaserin Clears Cardiovascular Safety Hurdle: CAMELLIA-TIMI 61

Michael O'Riordan

August 26, 2018

News Daily News

Genetic Risk Score Identifies Individuals at Heightened Risk of CAD and Other Diseases

Michael O'Riordan

August 16, 2018

News Daily News

Less Stroke With PCI at 5 Years, but CABG Risks Front-loaded in First 30 Days

Michael O'Riordan

July 19, 2018

News Daily News

SGLT2 Inhibitors Work in Type 2 Diabetes Across Levels of CV Risk, Renal Function

Todd Neale

July 02, 2018

News Daily News

Reduction in CVD Events, Even Mortality, in Patients With Diabetes Who Adopt a Healthier Lifestyle

Michael O'Riordan

June 18, 2018

Advertisement

Gasp! Cardiorespiratory Fitness Falling Over Time, Duke Study Suggests

Top News in Prevention: 2018

Now You See It: Imaging Helps Lower CVD Risk Burden in Primary Prevention

SYNTAX Score Should Not Guide Revascularization Strategy in FREEDOM-Like Patients

Higher Rates of Amputation and Ketoacidosis With SGLT2 Inhibitors: European Registry Data

PIONEER 6: Oral Semaglutide Passes Test in Cardiovascular Outcomes Study

EMPA-HEART Offers Mechanistic Clues for Empagliflozin’s Cardiac Benefits

Long-term FREEDOM: At Nearly 8 years, CABG Maintains Mortality Benefit Over PCI

Sit Less, Move More: New Physical Activity Guidelines Stress Movement at All Ages

New Cholesterol Guidelines Make Room for Non-Statin Therapy and CAC Screening

Big Fitness Equals Big Survival Benefit, New Study Shows

The Price of Knowledge: Industry-Sponsored Studies in the Era of Evidence-Based Medicine

Bariatric Surgery Reduces Hard CVD Events in Obese Patients With Type 2 Diabetes

Statin Benefits: Yes for CVD but No for Everything Else, Says New Review

Omega-3 Fatty Acids Fail to Reduce CVD Events in Diabetic Patients: ASCEND

Weight-Loss Drug Lorcaserin Clears Cardiovascular Safety Hurdle: CAMELLIA-TIMI 61

Genetic Risk Score Identifies Individuals at Heightened Risk of CAD and Other Diseases

Less Stroke With PCI at 5 Years, but CABG Risks Front-loaded in First 30 Days

SGLT2 Inhibitors Work in Type 2 Diabetes Across Levels of CV Risk, Renal Function

Reduction in CVD Events, Even Mortality, in Patients With Diabetes Who Adopt a Healthier Lifestyle

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content